JP2016520617A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520617A5
JP2016520617A5 JP2016517041A JP2016517041A JP2016520617A5 JP 2016520617 A5 JP2016520617 A5 JP 2016520617A5 JP 2016517041 A JP2016517041 A JP 2016517041A JP 2016517041 A JP2016517041 A JP 2016517041A JP 2016520617 A5 JP2016520617 A5 JP 2016520617A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
protecting group
heterocyclyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016517041A
Other languages
English (en)
Japanese (ja)
Other versions
JP6557654B2 (ja
JP2016520617A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/040231 external-priority patent/WO2014197313A2/en
Publication of JP2016520617A publication Critical patent/JP2016520617A/ja
Publication of JP2016520617A5 publication Critical patent/JP2016520617A5/ja
Application granted granted Critical
Publication of JP6557654B2 publication Critical patent/JP6557654B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016517041A 2013-05-30 2014-05-30 新規の化合物及びその使用 Expired - Fee Related JP6557654B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361829117P 2013-05-30 2013-05-30
US61/829,117 2013-05-30
US201361898719P 2013-11-01 2013-11-01
US61/898,719 2013-11-01
PCT/US2014/040231 WO2014197313A2 (en) 2013-05-30 2014-05-30 Novel compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2016520617A JP2016520617A (ja) 2016-07-14
JP2016520617A5 true JP2016520617A5 (https=) 2017-07-20
JP6557654B2 JP6557654B2 (ja) 2019-08-07

Family

ID=52008726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517041A Expired - Fee Related JP6557654B2 (ja) 2013-05-30 2014-05-30 新規の化合物及びその使用

Country Status (7)

Country Link
US (5) US9988386B2 (https=)
EP (1) EP3003314B1 (https=)
JP (1) JP6557654B2 (https=)
AU (1) AU2014275198B2 (https=)
CA (1) CA2913417A1 (https=)
HK (1) HK1223307A1 (https=)
WO (1) WO2014197313A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1223307A1 (zh) * 2013-05-30 2017-07-28 Kala Pharmaceuticals, Inc. 新型化合物和其用途
CA2962919C (en) * 2014-09-30 2024-01-02 Transitions Optical, Inc. Ultraviolet light absorbers
US10253045B2 (en) * 2014-11-26 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517080A (ja) * 2000-11-29 2004-06-10 グラクソ グループ リミテッド Tie−2および/またはvegfr−2の阻害剤として有用なベンゾイミダゾール誘導体
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
EP2058309A4 (en) * 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
AU2007279595A1 (en) 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
JPWO2009096435A1 (ja) * 2008-01-29 2011-05-26 武田薬品工業株式会社 縮合複素環誘導体およびその用途
WO2010032880A2 (en) 2008-09-19 2010-03-25 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
JP2010126530A (ja) * 2008-12-01 2010-06-10 Takeda Chem Ind Ltd 縮合複素環誘導体およびその用途
CN111700879A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
HK1223307A1 (zh) * 2013-05-30 2017-07-28 Kala Pharmaceuticals, Inc. 新型化合物和其用途

Similar Documents

Publication Publication Date Title
JP2016517417A5 (https=)
JP2016505637A5 (https=)
JP2019514956A5 (https=)
JP2017537940A5 (https=)
JP2016515560A5 (https=)
JP2016513130A5 (https=)
JP2021521178A5 (https=)
RU2016137678A (ru) Соединения с эфирными группами для лечения опосредованных комплементом нарушений
JP2019524883A5 (https=)
WO2017035355A1 (en) Ether compounds for treatment of medical disorders
JP2014500295A5 (https=)
JP2013502431A5 (https=)
JP2016503797A5 (https=)
JP2013515074A5 (https=)
JP2014511892A5 (https=)
JP2016531113A5 (https=)
RU2016114866A (ru) Замещенные аминопиримидиновые соединения и способы их использования
JP2017518360A5 (https=)
JP2014506582A5 (https=)
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
JP2013533883A5 (https=)
JP2021504317A5 (https=)
JP2019507111A5 (https=)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2016528245A5 (https=)